Company news

BioCryst Pharmaceuticals, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

BioCryst to Report First Quarter 2020 Financial Results on May 6

April 21, 2020

BioCryst Begins Clinical Trial with Galidesivir for Treatment of Patients with COVID-19

April 8, 2020

BioCryst Appoints Anthony Doyle Chief Financial Officer

April 1, 2020

BioCryst Begins Proof of Concept Trial in PNH Patients With Oral Factor D Inhibitor, BCX9930

March 4, 2020

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

March 1, 2020

BioCryst Appoints Alan G. Levin to Board of Directors

February 24, 2020

BioCryst to Report Fourth Quarter and Full Year 2019 Financial Results on March 5

February 19, 2020

FDA Accepts BioCryst’s NDA for Oral, Once Daily Berotralstat (BCX7353) to Prevent HAE Attacks

February 17, 2020

BioCryst Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

February 5, 2020

BioCryst Submits Japanese New Drug Application for Oral, Once Daily Berotralstat

February 2, 2020

BioCryst Strengthens Commercial Rare Disease Leadership

January 14, 2020

BioCryst Reports Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)

January 5, 2020

BioCryst Submits New Drug Application for Oral, Once Daily Berotralstat (BCX7353) to Prevent HAE Attacks

December 10, 2019

BioCryst Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares and Completion of Public Offering of Common Stock

November 17, 2019

BioCryst Prices Public Offering of Common Stock

November 12, 2019

BioCryst Commences Public Offering of Common Stock

November 11, 2019

BioCryst Reports Third Quarter 2019 Financial Results and Upcoming Key Milestones

November 5, 2019

BioCryst Announces Partnership With Torii Pharmaceutical to Commercialize BCX7353 in Japan for the Prevention of HAE Attacks

November 4, 2019

BioCryst Begins Phase 1 Trial With BCX9250, an Oral ALK-2 Inhibitor, for Treatment of Fibrodysplasia Ossificans Progressiva

October 31, 2019

BioCryst Reports Data From Phase 1 Trial of BCX9930 and Announces Plans to Advance Program Into Proof of Concept Study in PNH Patients

October 27, 2019

U.S. Government Exercises Option for Additonal Rapivab® for Strategic National Stockpile

September 25, 2019

BioCryst Appoints Helen Thackray, M.D., to Board of Directors

September 22, 2019

← Newer news releases

Calls

The 5 newest of 27 calls. Every call is listed under its year.

Decks

The 5 newest of 36 decks. Every deck is listed under its year.